Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ADUS vs UNH vs CVS vs HCSG vs ELV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Care Facilities
Medical - Healthcare Plans
ADUS vs UNH vs CVS vs HCSG vs ELV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Care Facilities | Medical - Healthcare Plans |
| Market Cap | $1.81B | $335.60B | $111.40B | $1.60B | $80.98B |
| Revenue (TTM) | $1.45B | $449.71B | $407.90B | $1.84B | $200.41B |
| Net Income (TTM) | $100M | $12.04B | $2.93B | $59M | $5.24B |
| Gross Margin | 32.5% | 18.8% | 13.9% | 13.3% | 23.2% |
| Operating Margin | 9.8% | 4.2% | 1.5% | 3.0% | 3.8% |
| Forward P/E | 14.1x | 20.2x | 12.2x | 20.8x | 13.9x |
| Total Debt | $209M | $78.39B | $93.59B | $25M | $33.23B |
| Cash & Equiv. | $82M | $24.36B | $8.51B | $161M | $9.49B |
ADUS vs UNH vs CVS vs HCSG vs ELV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Addus HomeCare Corp… (ADUS) | 100 | 98.3 | -1.7% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
| Healthcare Services… (HCSG) | 100 | 93.3 | -6.7% |
| Elevance Health Inc. (ELV) | 100 | 126.8 | +26.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ADUS vs UNH vs CVS vs HCSG vs ELV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ADUS is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 23.2%, EPS growth 23.2%, 3Y rev CAGR 14.4%
- 399.9% 10Y total return vs ELV's 202.1%
- Lower volatility, beta 0.58, Low D/E 19.2%, current ratio 1.80x
- PEG 0.70 vs ELV's 2.01
UNH lags the leaders in this set but could rank higher in a more targeted comparison.
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 13.9x)
- Beta 0.05 vs HCSG's 1.12
HCSG ranks third and is worth considering specifically for momentum and efficiency.
- +55.8% vs ADUS's -13.4%
- 7.3% ROA vs CVS's 1.1%, ROIC 9.0% vs 5.0%
Among these 5 stocks, ELV doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.2% revenue growth vs HCSG's 7.1% | |
| Value | Lower P/E (12.2x vs 13.9x) | |
| Quality / Margins | 6.9% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs HCSG's 1.12 | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +55.8% vs ADUS's -13.4% | |
| Efficiency (ROA) | 7.3% ROA vs CVS's 1.1%, ROIC 9.0% vs 5.0% |
ADUS vs UNH vs CVS vs HCSG vs ELV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ADUS vs UNH vs CVS vs HCSG vs ELV — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CVS leads in 2 of 6 categories
HCSG leads 2 • ADUS leads 1 • UNH leads 0 • ELV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ADUS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 310.5x ADUS's $1.4B. ADUS is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to CVS's 0.7%. On growth, ADUS holds the edge at +7.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.4B | $449.7B | $407.9B | $1.8B | $200.4B |
| EBITDAEarnings before interest/tax | $159M | $23.2B | $10.5B | $72M | $8.9B |
| Net IncomeAfter-tax profit | $100M | $12.0B | $2.9B | $59M | $5.2B |
| Free Cash FlowCash after capex | $137M | $19.7B | $7.4B | $139M | $6.5B |
| Gross MarginGross profit ÷ Revenue | +32.5% | +18.8% | +13.9% | +13.3% | +23.2% |
| Operating MarginEBIT ÷ Revenue | +9.8% | +4.2% | +1.5% | +3.0% | +3.8% |
| Net MarginNet income ÷ Revenue | +6.9% | +2.7% | +0.7% | +3.2% | +2.6% |
| FCF MarginFCF ÷ Revenue | +9.5% | +4.4% | +1.8% | +7.6% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.7% | +2.0% | +6.2% | +6.6% | +2.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +17.2% | +0.7% | +63.1% | +175.0% | -16.8% |
Valuation Metrics
CVS leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 14.8x trailing earnings, ELV trades at a 76% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), ADUS offers better value at 0.93x vs ELV's 2.15x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.8B | $335.6B | $111.4B | $1.6B | $81.0B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $389.6B | $196.5B | $1.5B | $104.7B |
| Trailing P/EPrice ÷ TTM EPS | 18.67x | 27.95x | 62.81x | 27.54x | 14.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.12x | 20.19x | 12.19x | 20.83x | 13.93x |
| PEG RatioP/E ÷ EPS growth rate | 0.93x | — | — | — | 2.15x |
| EV / EBITDAEnterprise value multiple | 12.52x | 16.70x | 13.11x | 22.38x | 10.84x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | 0.75x | 0.28x | 0.87x | 0.41x |
| Price / BookPrice ÷ Book value/share | 1.65x | 3.31x | 1.47x | 3.19x | 1.88x |
| Price / FCFMarket cap ÷ FCF | 17.48x | 20.88x | 14.27x | 11.49x | 25.51x |
Profitability & Efficiency
HCSG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ELV delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $4 for CVS. HCSG carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), ADUS scores 7/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.3% | +11.5% | +3.9% | +11.8% | +11.9% |
| ROA (TTM)Return on assets | +7.0% | +3.9% | +1.1% | +7.3% | +4.3% |
| ROICReturn on invested capital | +8.8% | +9.2% | +5.0% | +9.0% | +9.1% |
| ROCEReturn on capital employed | +10.9% | +9.7% | +6.1% | +7.7% | +8.2% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 6 | 5 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.19x | 0.77x | 1.24x | 0.05x | 0.75x |
| Net DebtTotal debt minus cash | $127M | $54.0B | $85.1B | -$136M | $23.7B |
| Cash & Equiv.Liquid assets | $82M | $24.4B | $8.5B | $161M | $9.5B |
| Total DebtShort + long-term debt | $209M | $78.4B | $93.6B | $25M | $33.2B |
| Interest CoverageEBIT ÷ Interest expense | 14.45x | 4.71x | 2.11x | 33.02x | 5.39x |
Total Returns (Dividends Reinvested)
HCSG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $7,888 for HCSG. Over the past 12 months, HCSG leads with a +55.8% total return vs ADUS's -13.4%. The 3-year compound annual growth rate (CAGR) favors HCSG at 14.1% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -8.7% | +10.6% | +10.6% | +28.6% | +5.8% |
| 1-Year ReturnPast 12 months | -13.4% | -3.2% | +34.7% | +55.8% | -9.0% |
| 3-Year ReturnCumulative with dividends | +16.3% | -19.9% | +36.6% | +48.6% | -15.6% |
| 5-Year ReturnCumulative with dividends | +0.0% | -2.6% | +17.0% | -21.1% | +1.5% |
| 10-Year ReturnCumulative with dividends | +399.9% | +220.6% | +3.5% | -26.8% | +202.1% |
| CAGR (3Y)Annualised 3-year return | +5.2% | -7.1% | +11.0% | +14.1% | -5.5% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than HCSG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs ADUS's 78.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.58x | 0.59x | 0.05x | 1.12x | 0.46x |
| 52-Week HighHighest price in past year | $124.44 | $395.52 | $88.63 | $24.39 | $424.24 |
| 52-Week LowLowest price in past year | $90.89 | $234.60 | $58.35 | $12.66 | $273.71 |
| % of 52W HighCurrent price vs 52-week peak | +78.2% | +93.5% | +98.5% | +91.5% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 75.9 | 69.3 | 61.8 | 75.5 |
| Avg Volume (50D)Average daily shares traded | 236K | 7.9M | 7.4M | 676K | 1.9M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ADUS as "Buy", UNH as "Buy", CVS as "Buy", HCSG as "Hold", ELV as "Buy". Consensus price targets imply 32.3% upside for ADUS (target: $129) vs 2.5% for ELV (target: $382). For income investors, CVS offers the higher dividend yield at 3.06% vs ELV's 1.85%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $128.67 | $385.43 | $95.20 | $24.50 | $382.38 |
| # AnalystsCovering analysts | 15 | 52 | 41 | 15 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% | +3.1% | — | +1.8% |
| Dividend StreakConsecutive years of raises | 2 | 25 | 0 | 20 | 15 |
| Dividend / ShareAnnual DPS | — | $8.70 | $2.67 | — | $6.89 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | 0.0% | +3.9% | +3.2% |
CVS leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). HCSG leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
ADUS vs UNH vs CVS vs HCSG vs ELV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ADUS or UNH or CVS or HCSG or ELV a better buy right now?
For growth investors, Addus HomeCare Corporation (ADUS) is the stronger pick with 23.
2% revenue growth year-over-year, versus 7. 1% for Healthcare Services Group, Inc. (HCSG). Elevance Health Inc. (ELV) offers the better valuation at 14. 8x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate Addus HomeCare Corporation (ADUS) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ADUS or UNH or CVS or HCSG or ELV?
On trailing P/E, Elevance Health Inc.
(ELV) is the cheapest at 14. 8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Addus HomeCare Corporation wins at 0. 70x versus Elevance Health Inc. 's 2. 01x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — ADUS or UNH or CVS or HCSG or ELV?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -21. 1% for Healthcare Services Group, Inc. (HCSG). Over 10 years, the gap is even starker: ADUS returned +399. 9% versus HCSG's -26. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ADUS or UNH or CVS or HCSG or ELV?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Healthcare Services Group, Inc. 's 1. 12β — meaning HCSG is approximately 2120% more volatile than CVS relative to the S&P 500. On balance sheet safety, Healthcare Services Group, Inc. (HCSG) carries a lower debt/equity ratio of 5% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — ADUS or UNH or CVS or HCSG or ELV?
By revenue growth (latest reported year), Addus HomeCare Corporation (ADUS) is pulling ahead at 23.
2% versus 7. 1% for Healthcare Services Group, Inc. (HCSG). On earnings-per-share growth, the picture is similar: Healthcare Services Group, Inc. grew EPS 52. 8% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, ADUS leads at 14. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ADUS or UNH or CVS or HCSG or ELV?
Addus HomeCare Corporation (ADUS) is the more profitable company, earning 6.
7% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 6. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADUS leads at 9. 7% versus 2. 6% for CVS. At the gross margin level — before operating expenses — ADUS leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ADUS or UNH or CVS or HCSG or ELV more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Addus HomeCare Corporation (ADUS) is the more undervalued stock at a PEG of 0. 70x versus Elevance Health Inc. 's 2. 01x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CVS Health Corporation (CVS) trades at 12. 2x forward P/E versus 20. 8x for Healthcare Services Group, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADUS: 32. 3% to $128. 67.
08Which pays a better dividend — ADUS or UNH or CVS or HCSG or ELV?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), ELV (1. 8% yield) pay a dividend. ADUS, HCSG do not pay a meaningful dividend and should not be held primarily for income.
09Is ADUS or UNH or CVS or HCSG or ELV better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, HCSG: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ADUS and UNH and CVS and HCSG and ELV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ADUS is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; HCSG is a small-cap quality compounder stock; ELV is a mid-cap deep-value stock. UNH, CVS, ELV pay a dividend while ADUS, HCSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.